technology:chemotherapy

  • Eleanor Draeger: We have reached the point where we should consider compulsory vaccination - The BMJ
    https://blogs.bmj.com/bmj/2019/05/17/eleanor-draeger-we-have-reached-the-point-where-we-should-consider-compul

    The time for gently nudging parents to vaccinate their children is over. A groundswell of antivaccine opinion and fake news from a highly influential and malicious antivax lobby is managing to harness social media for its own ends. As a result, in the UK, uptake of measles, mumps, and rubella (MMR) vaccine has fallen to below the level needed to create herd immunity. Vaccination coverage is currently 91% across the UK, which falls short of the 95% that is needed for herd immunity. This is putting the most vulnerable children in our society at risk. For there are some children who cannot have the MMR vaccine—either because they are too young or because they have a medical condition that means that it is not safe for them to have a live vaccine. This includes children with cancer, who cannot have the vaccine while they are being treated with chemotherapy because they are immunosuppressed.

    #vaccination #vaccins #santé

  • The family that took on Monsanto: ’They should’ve been with us in the chemo ward’ | Business | The Guardian
    https://www.theguardian.com/business/2019/apr/10/edwin-hardeman-monsanto-trial-interview

    Becoming ‘the face’ of the fight
    Advertisement

    Edwin Hardeman and his wife, Mary, never expected that they would become de facto leaders of the federal court fight against the world’s most widely used weedkiller. They just wanted Monsanto to acknowledge the dangers – and potentially save other families from the horror they endured.

    “This is something that was egregious to me. It was my personal battle and I wanted to take it full circle,” said Edwin, whose cancer is now in remission. “It’s been a long journey.”

    Mary bristled when she thought about Monsanto’s continued defense of its chemical: “They should have been with us when we were in the chemo ward … not knowing what to do to relieve the pain.

    “I get angry,” she added. “Very angry.”

    Monsanto first put Roundup on the market in 1974, presenting the herbicide, which uses a chemical called glyphosate, as a breakthrough that was effective at killing weeds and safe. The product has earned the corporation billions in revenue a year, and glyphosate is now ubiquitous in the environment – with traces in water, food and farmers’ urine.

    Hardeman didn’t recognize the term glyphosate when he saw the news report about the Iarc ruling on TV. At that time, the chemotherapy side effects had devastated him – causing violent nausea, swelling that made his face unrecognizable and terrifying feelings of electric shocks jolting his body.

    But when he realized that glyphosate was the main ingredient in Roundup and that research suggested it could be responsible for his form of NHL, diffuse large B-cell lymphoma, it clicked: “It just hit me. There’s something going on here.”

    He filed a lawsuit in February 2016. So did hundreds of other cancer survivors and families who lost loved ones, and many of the parallel suits were consolidated as one case under federal judge Vince Chhabria in San Francisco.

    The judge selected Hardeman to be first – the so-called “bellwether” trial, meaning it would be the official test case that would inform future litigation and potentially impact settlements for others.

    It was a lot of pressure.

    “Learning I was going to be the plaintiff, the one, the face of the … litigation, was a shock,” he said.

    The unsealed emails and documents suggested that Monsanto had an aggressive PR strategy for years that involved attacking negative research and ghostwriting and pushing favorable studies.

    In one email, a Monsanto executive advised others in the company to be cautious about how they describe the safety of the product, warning: “You cannot say that Roundup is not a carcinogen … we have not done the necessary testing on the formulation to make that statement.”
    Edwin and his wife, Mary, never expected that they would become de facto leaders of the federal court fight against the world’s most widely used weedkiller.

    Edwin and his wife, Mary, never expected that they would become de facto leaders of the federal court fight against the world’s most widely used weedkiller. Photograph: Brian Frank/The Guardian

    Monsanto officials also privately talked about the company writing science papers that would be officially authored by researchers, with one email saying: “We would be keeping the cost down by us doing the writing and they would just edit and sign their names.” The internal documents also shined a harsh light on Monsanto’s cozy relationship with US regulators and its media campaign to combat the Iarc ruling.

    (The company has said it was open about its involvement in research.)

    One executive eventually revealed that the company had a roughly $17m budget for PR and public affairs related to Iarc and glyphosate.

    The unusual and severe limitations made the message of the victory all the more powerful, Wagstaff said in an interview: “We were forced, over our objections, to argue just the science. Any argument by Bayer or Monsanto that this was a sympathetic jury to Mr Hardeman … is just not supported by the facts.”

    Mary, who was home sick the day the jury announced, first saw the verdict on Twitter before her husband could break the news: “I let out a scream. It’s a wonder one of my neighbors didn’t come in.”

    With the cancer science proven, Hardeman’s legal team was finally allowed to present evidence and arguments about Monsanto’s “despicable” and “reckless” behavior – and that was a success, too. The jury ruled Monsanto was negligent and owed him $80m in damages.

    Within minutes of the final verdict, a Bayer spokesperson issued a response: The company would appeal.

    In US federal court, there are around 1,200 plaintiffs with similar Roundup cancer cases – and roughly 11,000 nationwide. Despite two jury rulings saying Roundup causes cancer, the corporation’s defense has not changed: Roundup is safe for use.

    “We continue to believe strongly in the extensive body of reliable science that supports the safety of Roundup and on which regulators around the world continue to base their own favorable assessments,” a Bayer spokesperson told the Guardian. “Our customers have relied on these products for more than 40 years and we are gratified by their continued support.”

    Bayer, which has faced backlash from investors and a share price drop in the wake of the Roundup controversy, could be pushed to negotiate a massive settlement with plaintiffs following Hardeman’s victory.

    Hardeman said the very least the company could do is warn consumers: “Give us a chance to decide whether we want to use it or not … Have some compassion for people.”

    Hardeman said it also disturbed him that Bayer and Monsanto still have not done their own study on the carcinogenicity of Roundup, even after all these years. (Monsanto has said the company has gone beyond what was required in testing glyphosate exposure risks.)

    “I worry about the younger generation,” Hardeman said. “Why haven’t you tested this product? Why, why, why? You’ve got the money. Are you afraid of the answer?”

    #Roundup #Perturbateurs_endocriniens #Pesticides #Monsanto #Bayer

  • Is Marijuana as Safe as We Think ? | The New Yorker
    https://www.newyorker.com/magazine/2019/01/14/is-marijuana-as-safe-as-we-think

    A few years ago, the National Academy of Medicine convened a panel of sixteen leading medical experts to analyze the scientific literature on cannabis. The report they prepared, which came out in January of 2017, runs to four hundred and sixty-eight pages. It contains no bombshells or surprises, which perhaps explains why it went largely unnoticed. It simply stated, over and over again, that a drug North Americans have become enthusiastic about remains a mystery.

    For example, smoking pot is widely supposed to diminish the nausea associated with chemotherapy. But, the panel pointed out, “there are no good-quality randomized trials investigating this option.” We have evidence for marijuana as a treatment for pain, but “very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States.” The caveats continue. Is it good for epilepsy? “Insufficient evidence.” Tourette’s syndrome? Limited evidence. A.L.S., Huntington’s, and Parkinson’s? Insufficient evidence. Irritable-bowel syndrome? Insufficient evidence. Dementia and glaucoma? Probably not. Anxiety? Maybe. Depression? Probably not.

    Then come Chapters 5 through 13, the heart of the report, which concern marijuana’s potential risks. The haze of uncertainty continues. Does the use of cannabis increase the likelihood of fatal car accidents? Yes. By how much? Unclear. Does it affect motivation and cognition? Hard to say, but probably. Does it affect employment prospects? Probably. Will it impair academic achievement? Limited evidence. This goes on for pages.

    We need proper studies, the panel concluded, on the health effects of cannabis on children and teen-agers and pregnant women and breast-feeding mothers and “older populations” and “heavy cannabis users”; in other words, on everyone except the college student who smokes a joint once a month. The panel also called for investigation into “the pharmacokinetic and pharmacodynamic properties of cannabis, modes of delivery, different concentrations, in various populations, including the dose-response relationships of cannabis and THC or other cannabinoids.”

    Not surprisingly, the data we have are messy. Berenson, in his role as devil’s advocate, emphasizes the research that sees cannabis as opening the door to opioid use. For example, two studies of identical twins—in the Netherlands and in Australia—show that, in cases where one twin used cannabis before the age of seventeen and the other didn’t, the cannabis user was several times more likely to develop an addiction to opioids. Berenson also enlists a statistician at N.Y.U. to help him sort through state-level overdose data, and what he finds is not encouraging: “States where more people used cannabis tended to have more overdoses.”

    The National Academy panel is more judicious. Its conclusion is that we simply don’t know enough, because there haven’t been any “systematic” studies. But the panel’s uncertainty is scarcely more reassuring than Berenson’s alarmism. Seventy-two thousand Americans died in 2017 of drug overdoses. Should you embark on a pro-cannabis crusade without knowing whether it will add to or subtract from that number?

    Drug policy is always clearest at the fringes. Illegal opioids are at one end. They are dangerous. Manufacturers and distributors belong in prison, and users belong in drug-treatment programs. The cannabis industry would have us believe that its product, like coffee, belongs at the other end of the continuum. “Flow Kana partners with independent multi-generational farmers who cultivate under full sun, sustainably, and in small batches,” the promotional literature for one California cannabis brand reads. “Using only organic methods, these stewards of the land have spent their lives balancing a unique and harmonious relationship between the farm, the genetics and the terroir.” But cannabis is not coffee. It’s somewhere in the middle. The experience of most users is relatively benign and predictable; the experience of a few, at the margins, is not.

    The National Academy panel is more judicious. Its conclusion is that we simply don’t know enough, because there haven’t been any “systematic” studies. But the panel’s uncertainty is scarcely more reassuring than Berenson’s alarmism. Seventy-two thousand Americans died in 2017 of drug overdoses. Should you embark on a pro-cannabis crusade without knowing whether it will add to or subtract from that number?

    Drug policy is always clearest at the fringes. Illegal opioids are at one end. They are dangerous. Manufacturers and distributors belong in prison, and users belong in drug-treatment programs. The cannabis industry would have us believe that its product, like coffee, belongs at the other end of the continuum. “Flow Kana partners with independent multi-generational farmers who cultivate under full sun, sustainably, and in small batches,” the promotional literature for one California cannabis brand reads. “Using only organic methods, these stewards of the land have spent their lives balancing a unique and harmonious relationship between the farm, the genetics and the terroir.” But cannabis is not coffee. It’s somewhere in the middle. The experience of most users is relatively benign and predictable; the experience of a few, at the margins, is not.

    Late last year, the commissioner of the Food and Drug Administration, Scott Gottlieb, announced a federal crackdown on e-cigarettes. He had seen the data on soaring use among teen-agers, and, he said, “it shocked my conscience.” He announced that the F.D.A. would ban many kinds of flavored e-cigarettes, which are especially popular with teens, and would restrict the retail outlets where e-cigarettes were available.

    In the dozen years since e-cigarettes were introduced into the marketplace, they have attracted an enormous amount of attention. There are scores of studies and papers on the subject in the medical and legal literature, grappling with the questions raised by the new technology. Vaping is clearly popular among kids. Is it a gateway to traditional tobacco use? Some public-health experts worry that we’re grooming a younger generation for a lifetime of dangerous addiction. Yet other people see e-cigarettes as a much safer alternative for adult smokers looking to satisfy their nicotine addiction. That’s the British perspective. Last year, a Parliamentary committee recommended cutting taxes on e-cigarettes and allowing vaping in areas where it had previously been banned. Since e-cigarettes are as much as ninety-five per cent less harmful than regular cigarettes, the committee argued, why not promote them? Gottlieb said that he was splitting the difference between the two positions—giving adults “opportunities to transition to non-combustible products,” while upholding the F.D.A.’s “solemn mandate to make nicotine products less accessible and less appealing to children.” He was immediately criticized.

    “Somehow, we have completely lost all sense of public-health perspective,” Michael Siegel, a public-health researcher at Boston University, wrote after the F.D.A. announcement:

    #Santé_publique #Marijuana

  • How to Win the War on Cancer - YouTube
    https://www.youtube.com/watch?v=l_C26gt1LbA

    How effective is chemotherapy for colon, lung, breast, and prostate cancer?

    https://nutritionfacts.org/video/how-to-win-the-war-on-cancer

    If you look at the contribution of cancer-killing chemo to five-year survival in cancer patients, it’s on the order of only about 2%. Now, there’s some pediatric cancers we’ve gotten good at treating, and testicular cancer and Hodgkin’s disease are exceptions, but if you look at our most common cancers—colon, lung, breast, and prostate—the success rate is only about 1%. Meaning like, out of nearly 14,000 colon cancer patients, only 146 lived out five years thanks to chemotherapy. So, the chance of survival benefit is like one in a hundred, but doctors don’t tell patients that. “…[N]ew chemotherapy drug[s are] promoted as…major breakthrough[s], only to be later [quietly] rejected.” “The minimal impact on survival in the more common cancers conflicts with the perceptions of many patients who feel they are receiving a treatment that will significantly enhance their chances of cure.”

    #cancer #chimiothérapie #prévention #nutritionfacts

  • Why #cbd Needs to be Part of Your Medical Regimen
    https://hackernoon.com/why-cbd-needs-to-be-part-of-your-medical-regimen-2ba8c5329b52?source=rss

    In a world where prescriptions are king and synthetic pharmaceuticals rule the medical community, finding reliable natural or homeopathic remedies can be a challenge. However for patients who have not found solutions for their conditions from “traditional” treatment, CBD, or Cannabidiol, has been something of a miracle cure. Reacting directly with the serotonin receptors in the body, CBD helps restore these natural neurotransmitters, helping the body to help itself.For individuals who suffer from minor motion sickness, chronic vertigo, and even chemotherapy related nausea, CBD treats these symptoms effectively and safely. One in four cancer patients, traditional treatments to manage nausea and vomiting have little to no effect. In these individuals, doses of CBD have been shown to (...)

    #cbd-oils #health #cannabis #infographics

  • Breast #cancer : Test means fewer women will need chemotherapy - BBC News
    https://www.bbc.com/news/health-44347381

    Currently, women who get a low score on the test are told they do not need chemo, those with a high score are told they definitely do.

    But most women get an intermediate result meaning they are unclear as to what to do.

    Data presented at the world’s biggest meeting of cancer doctors and scientists in Chicago shows these women have the same survival rates with or without chemo.

    The nine-year-survival-rate was 93.9% without chemotherapy and 93.8% with chemotherapy.

    [...]

    The study is strictly about early stage breast cancers - specifically those that can still be treated with hormone therapy, have not spread to the lymph nodes and do not have the HER2 mutation, which makes them grow more quickly.

    The test is performed on a sample of the tumour when it is removed during surgery.

    It works by looking at the activity levels of 21 genes, which are markers of how aggressive the cancer is.

    #Cancer_du_sein : des milliers de femmes pourront demain éviter la #chimiothérapie | E-#Santé
    http://www.e-sante.fr/cancer-du-sein-des-milliers-de-femmes-pourront-demain-eviter-la-chimiotherapie/breve/61546

  • This Man’s Immune System Got a Cancer-killing Update - Facts So Romantic
    http://nautil.us/blog/this-mans-immune-system-got-a-cancer_killing-update

    William Ludwig was almost dead when he became Patient Number One in a radical new cancer treatment, one that’s just won the endorsement of F.D.A. advisors.Photograph by sebastianosecondi / ShutterstockWilliam Ludwig was a 64-year-old retired corrections officer living in Bridgeton, New Jersey, in 2010, when he received a near-hopeless cancer prognosis. The Abramson Cancer Center at the University of Pennsylvania had run out of chemotherapeutic options, and Ludwig was disqualified from most clinical trials since he had three cancers at once—leukemia, lymphoma, and squamous cell skin cancer. In a later interview, the scientist Carl June described Ludwig’s condition as “Almost dead.” Alison Loren, an oncologist at Penn, had been taking care of Ludwig for five painful years. If chemotherapy is (...)

  • Palestinian succumbs to gunshot wounds inflicted 3 months ago by Israeli forces
    Feb. 10, 2017 5:33 P.M. (Updated : Feb. 10, 2017 5:34 P.M.)
    http://www.maannews.com/Content.aspx?ID=775403

    BETHLEHEM (Ma’an) – A Palestinian held in Israeli custody succumbed to his wounds on Friday after being shot by Israeli forces in Nov. for allegedly attempting to carry out a stabbing attack.

    Issa Qaraqe, the head of the Palestinian Committee of Prisoners’ Affairs, told Ma’an that 24-year-old Muhammad al-Jallad (also reported as Muhammad Amr) died in Israeli custody while at the Beilinson Hospital in the city of Petah Tikva in central Israel.

    Al-Jallad was shot by Israeli forces on Nov. 9, 2016 at the Huwwara military checkpoint in the southern part of the occupied West Bank district of Nablus, Qaraqe said.

    Israeli authorities claimed that al-Jallad had attempted to stab an Israeli soldier with a screwdriver before Israeli forces opened live fire on him.

    According to Qaraqe, Israeli forces took al-Jallad into custody at the time and transported him to Beilinson hospital for treatment.

    Qaraqe added that al-Jallad had also suffered from lymphoma.

    Nov. 9, 2016 9:40 A.M. (Updated : Nov. 10, 2016 10:25 A.M.)
    http://www.maannews.com/Content.aspx?id=773882

    (...) Abdullah Abu Salim, 43, a merchant from Huwwara, told Ma’an at the scene that he and two of his friends, “saw [Amr] attempting to cross the road in Huwwara before being shot at by an Israeli soldier who then took out a knife and threw it next to the youth.”(...)

    #Palestine_assassinée

    • Palestinian Dies After Being Shot by Israeli Troops on His Way to His Last Chemo Session

      No one bothered to keep the young Palestinian’s family informed.
      Gideon Levy and Alex Levac Feb 17, 2017 9:52 AM
      read more: http://www.haaretz.com/israel-news/.premium-1.772183

      Mohammed-Aamar Jalad’s father, Thabath. - photo Alec Levac

      On his way to what was supposed to his final chemotherapy session, last November, he boarded the wrong shared taxi. Discovering his mistake, he got off and ran across the highway to catch a taxi going in the opposite direction. Israel Defense Forces soldiers who may have thought he was going to attack them, shot him, seriously wounding him. For the next three months, he was bedridden in Beilinson Hospital, in Petah Tikva, most of the time in the intensive care unit. Throughout that entire period, no one in the IDF thought of updating his parents and family about the condition of their loved one. His mother was the only one allowed who was supposed to be allowed to visit him, but even though she came a few times, on all but one occasion, she was not permitted to enter his room.

      Just as his condition seemed to be improving, he died, apparently last week. No one thought to inform the family about his death, or the circumstances surrounding it. Israel has not yet returned the body.

      In his native town of Tul Karm, in the northwestern part of the West Bank, no one believes that Mohammed-Aamar Jalad tried to attack soldiers on the way to his last chemo session. His father is the city’s legendary driving instructor – 45 years behind the wheel – and his grandfather was the first local resident to serve in the Israel Police. A photo of the grandfather in uniform hangs on a wall of Mohammed’s family’s house.

      This, then, was the life and death of the 25-year-old student, who dreamed of living in the United States, and who in 2010 won a U.S. green card through the lottery – but had fulfillment of his dream delayed by cancer, and terminated by Israeli soldiers.

      When we visited last weekend, women paying their condolences were going up and down the stairs leading to the elegant home in Tul Karm, which is shrouded in mourning. Mohammed’s sister, Samar, the dean of the nursing school at Ramallah’s Community College, and her father, Thabath, the driving teacher, greet us.

      It’s a very restrained, dignified home. The family is apolitical, we’re told by Abdulkarim Sadi, a field researcher for B’Tselem, the Israeli human rights organization.

      Mohammed was the youngest son; his two brothers live in the Persian Gulf region. A year ago, he was diagnosed with Hodgkin lymphoma. At that time, he’d completed two years of accountancy studies at Al-Quds Open University and had signed up for additional studies at the Ramallah college. His illness forced him to put his academic aspirations on hold. He was treated at An-Najah National University Hospital in Nablus, in biweekly intravenous chemotherapy sessions. The disease was in recession and he felt good.

      Wednesday, November 9, 2016, was set as the date for the final treatment. Samar called him that morning to ask if he was going to the hospital, and he replied that he was. At 7:30 A.M., his father took him to the Tul Karm central bus station, leaving him at the stand of shared-taxis heading to Nablus. The taxis for Ramallah were parked across the way, and Mohammed accidentally boarded one of them. He only realized his mistake next to the turnoff to the settlement of Yitzhar. The driver suggested that he get off at Hawara Junction, next to the checkpoint of that name, where he would be able to pick up the taxi to Nablus.

      Mohammed took his advice; after getting out of the vehicle, he had to cross the highway. He did so on the run. On the other side was an IDF jeep and a few soldiers, who were guarding the busy junction. The soldiers apparently thought that he was out to attack them.

      Mohammed was shot as he reached the middle of the road – one bullet to the stomach. He collapsed, bleeding. Just then, a Palestinian ambulance happened by, taking a patient from Jenin to the Allenby Bridge. The driver, Osama Nazal, wanted to assist him, but the soldiers and police who had arrived in the meantime kept him from evacuating the injured man. More forces arrived, along with an Israeli ambulance, which took Mohammed to Beilinson Hospital. Nazal later told Mohammed’s parents that their son was still fully conscious at that time.

      Some time later, the father got a call from Palestinian Preventive Security, asking him to come to the organization’s offices. Thabath waited until he’d finished the driving lesson he was giving before going. He says he thought he’d been summoned because his son had been involved in a quarrel with another passenger. He never imagined the news that awaited him. As he was sitting there, hearing only that his son had been hurt – he got a call asking him to come to the office of the Shin Bet security service at the Sha’ar Ephraim checkpoint, near Tul Karm.

      Thabath was met there by Agent “Karim,” whom he describes as being very polite when questioning him about his son. However, Karim, too, declined to tell him anything about Mohammed’s condition, or even whether he was alive or dead. In the meantime, one of Thabath’s friends told him that his son had been taken to Beilinson. Thabath drove home to get his wife, and the two set out for Sha’ar Ephraim in the hope that they would be allowed to pass through the checkpoint – as they should have been, because they are both over 55 – and get quickly to Beilinson. But they were stopped and peremptorily sent back without an explanation.

      From that moment, the family was plunged into three months of torment and mental abuse, during which the darkness of uncertainty about their son’s condition hung over their lives, and they swung back and forth between despair and hope. Never were they successful in receiving authoritative information. They knew Mohammed was in ICU in serious condition, in an induced coma and hooked up to a ventilator; at some point, the family, which they received informaton from their lawyer and from sympathetic medical staff, heard that his condition had improved. They sent information about his bout with lymphoma to the hospital and hoped for the best.

      Over those three months, Mohammed’s father was continually denied entry to Israel to visit his son. His wife, Maisir, was issued a permit on four occasions, but on three of them, after making the trip, she was blocked from entering Mohammed’s room by the soldier-warders guarding it. Once, they let her see him from the door for an instant; once they let her in for about two minutes, to caress him. His condition improved from one visit to the next. The doctors and nurses told Maisir he had regained consciousness and had been taken off the ventilator.

      A few days before his death, he was moved from ICU to the surgical ward. Throughout the period, he continued to be remanded in custody by an Israeli military court.

      For her part, Maisir went to visit for the last time on January 23. Again she was denied entry to his room, and only allowed to talk to the medical personnel. Dr. Kamal Natour, from the Palestinian Prisoners Club, a voluntary organization made up of former Israeli detainees, visited Mohammed at the time and reported to the family. They understood that he was getting better and had begun to eat. Then a few days went by without any news. Maisir had a sense of foreboding. She says now that throughout the three months, she barely slept for worry about her son, but last week she became even more worried.

      Last Friday, Maisir decided to call one of the physicians from the ICU, Dr. Jihad Bishara, whom she had met. Her daughter helped her find his number online, after she recognized a photo of him. He told her Mohammed had been transferred out of his unit; he’d been off that day, but he promised to look into the situation and get back to her. Maisir insisted on calling him again. She was very unsettled about her son’s condition, despite the recent optimistic reports.

      “Do you believe in God?” Dr. Bishara asked her when she called him again. “Your son is dead.”

      The doctor then called the family back shortly afterward, this time to inform them officially in the name of the hospital that Mohammed had died. But to this day, they don’t know when their son died and above all, the cause of death.

      This week, we asked the IDF Spokesperson’s Unit five questions:

      1. Why was Mohammed Jalad shot by the soldiers?

      2. Why was his family not allowed to visit him in the hospital?

      3. Why did his parents not receive an authoritative report about his condition?

      4. Why didn’t the IDF bother to inform them of his death and the reasons for his death?

      5. Why hasn’t his body been returned?

      The IDF Spokespersons Unit responded with the following statement: “On November 9, 2016, Mohammed-Amar Jalad carried out a knifing attack on soldiers at the Hawara checkpoint, using a knife sharpener. The force responded with fire, wounding the terrorist, who was evacuated to Beilinson Hospital for treatment.”

      Together with the mourning and grief, the family living in this sedate home in Tul Karm is reeling under a cloud of helplessness and lack of information. What did their loved one die of? Why was he arrested? What must they do to get possession of the body? Time and again they asked, and time and again their questions hung suspended in the air, unanswered.

    • Israel to return body of Palestinian who succumbed to injuries a week earlier
      Feb. 16, 2017 4:30 P.M. (Updated: Feb. 16, 2017 9:36 P.M.)
      http://www.maannews.com/Content.aspx?id=775506

      TULKAREM (Ma’an) — Israeli authorities will return the body of slain Palestinian Muhammad al-Jallad at 3 p.m. on Friday at the Enav checkpoint in the northern occupied West Bank district of Tulkarem, according to the Palestinian Committee of Prisoners’ Affairs.

      Al-Jallad — also known as Muhammad Amr — died on Feb. 10 in Israel’s Beilinson Hospital from injuries he sustained after Israeli forces shot him in the chest on Nov. 9, 2016 at the Huwwara checkpoint south of Nablus following an alleged stabbing attempt.

  • Sick for Attention - Issue 42 : Fakes
    http://nautil.us/issue/42/fakes/sick-for-attention

    Marc Feldman has spent more than 25 years studying fakes, but the bespectacled Alabama-based psychiatrist still vividly recalls the woman who introduced him to what became his life’s work. It was in the early 1990s, when he was a newly minted psychiatrist, shortly after completing his residency at Duke University. His department chair asked him to see a patient he calls “Anna,” who was suffering from an unusual psychological disorder. The woman sitting in the brightly lit exam room was emaciated, and her gaunt body was virtually devoid of flesh with an ill-fitting brown wig sitting on her shaved head. She was in her 30s and had been employed in a position of some responsibility. Anna’s alarming appearance was presumably the result of several grueling rounds of chemotherapy for her (...)

  • Cancer drugs, survival, and ethics | The BMJ
    http://www.bmj.com/content/355/bmj.i5792.full
    La #chimiothérapie contribue très peu à la #survie des patients atteints de #cancer. Et elle coûte très cher.

    A meta-analysis published in 2004 explored the contribution of cytotoxic chemotherapy to five year survival in 250 000 adults with solid cancers from Australian and US randomised trials.3 An important effect was shown on five year survival only in testicular cancer (40%), Hodgkin’s disease (37%), cancer of the cervix (12%), lymphoma (10.5%), and ovarian cancer (8.8%). Together, these represented less than 10% of all cases. In the remaining 90% of patients—including those with the commonest tumours of the lung, prostate, colorectum, and breast—drug therapy increased five year survival by less than 2.5%—an overall survival benefit of around three months.3 Similarly, 14 consecutive new drug regimens for adult solid cancers approved by the European Medicines Agency provided a median 1.2 months overall survival benefit against comparator regimens.4 Newer drugs did no better: 48 new regimens approved by the US Food and Drug Administration between 2002 and 2014 conferred a median 2.1 month overall survival benefit.5 Drug treatment can therefore only partly explain the 20% improvement in five year survival mentioned above. Developments in early diagnosis and treatment may have contributed much more.6

    The approval of drugs with such small survival benefits raises ethical questions, including whether recipients are aware of the drugs’ limited benefits, whether the high cost:benefit ratios are justified, and whether trials are providing the right information.

  • Measuring #financial_toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) - Souza - 2016 - Cancer
    http://onlinelibrary.wiley.com/doi/10.1002/cncr.30369/full

    #Cancer and its treatment lead to increased financial distress for patients. To the authors’ knowledge, to date, no standardized patient-reported outcome measure has been validated to assess this distress.

    METHODS

    Patients with AJCC Stage IV solid tumors receiving chemotherapy for at least 2 months were recruited. Financial toxicity was measured by the COmprehensive Score for financial Toxicity (COST) measure.

    (...)

    CONCLUSIONS

    The COST measure demonstrated reliability and validity in measuring financial toxicity. Its correlation with HRQOL indicates that financial toxicity is a clinically relevant patient-centered outcome.

    #santé #finance #sécurité_sociale #États-Unis

  • The superbug that doctors have been dreading just reached the U.S. | The Washington Post
    https://www.washingtonpost.com/news/to-your-health/wp/2016/05/26/the-superbug-that-doctors-have-been-dreading-just-reached-the-u-s

    For the first time, researchers have found a person in the United States carrying bacteria resistant to antibiotics of last resort, an alarming development that the top U.S. public health official says could mean “the end of the road” for antibiotics.

    The antibiotic-resistant strain was found last month in the urine of a 49-year-old Pennsylvania woman. Defense Department researchers determined that she carried a strain of E. coli resistant to the antibiotic colistin, according to a study published Thursday in Antimicrobial Agents and Chemotherapy, a publication of the American Society for Microbiology. The authors wrote that the discovery “heralds the emergence of a truly pan-drug resistant bacteria.”

  • Extremism & Incitement to Racial Hatred: Senior Israeli Officials in Their Own Words
    http://imeu.org/article/extremism-incitement-to-racial-hatred-senior-israeli-officials-in-their-own

    “A Jew always has a much higher soul than a gentile, even if he is a homosexual.”
    – Then-deputy minister of religious services and current deputy minister of defense, Rabbi Eli Ben-Dahan, 2013.

    “I am happy to be a fascist!”
    – Miri Regev, current minister of culture and sport, 2012.

    “[There are] 92,000 families in Israel in which one of the partners is not Jewish - we have a real problem that we have to deal with."
    – Tzipi Hotovely, current deputy foreign minister, 2011.

    “The Palestinian threat harbors cancer-like attributes that have to be severed. There are all kinds of solutions to cancer. Some say it’s necessary to amputate organs but at the moment I am applying chemotherapy.”
    – Then-general and current defense minister, Moshe Yaalon, 2002.

    “[The way to deal with Palestinians is to] beat them up, not once but repeatedly, beat them up so it hurts so badly, until it’s unbearable.”
    – Benjamin Netanyahu, current prime minister, while in the opposition following his first term as prime minister, caught on video speaking to Israeli settlers, 2001.

    #sionisme #sioniste #Israel #Israël #etat_raciste

  • Oncologist slams expensive chemo drugs at annual meeting | State Column
    http://www.statecolumn.com/2015/06/oncologist-slams-expensive-chemo-drugs-at-annual-meeting

    A top-level oncologist has just delivered a scathing critique of the exorbitant prices for many chemotherapy drugs at the annual meeting of the American Society for Clinical Oncology. According to Youth Health Magazine, Dr. Leanord Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center in New York went on a tirade against the ever-increasing cost of these critical medications during his speech at the meeting.

    Earlier during the day, representatives from pharmaceutical company Bristol-Meyers presented research that showed how a combination of two drugs they produced, Yervoy and Opdiva, significantly increased the length of lives in patients with melanoma. Saltz used the research as a starting point for his speech, noting that together they can cost a patient up to $295,000 each year.

    Saltz noted that the median monthly price for cancer drugs in the US has more than doubled in the past decade. The median price jumped from $4,716 each month from 2000 to 2004 to $ 9,900 each month between 2010 and 2014.

  • Sybille Paulsen uses cancer patients’ hair to form jewellery
    http://www.dezeen.com/2015/03/07/sybille-paulsen-cancer-patients-hair-chemotherapy-jewellery-tangible-truths

    Berlin-based designer Sybille Paulsen has worked with people undergoing chemotherapy treatment to create bespoke jewellery from their own hair.

    Sybille Paulsen’s Tangible Truths project enables cancer patients who cut off their hair, rather than lose it gradually as a result of chemotherapy treatment, to wear it in a different way.

    #design #cancer #Sybille_Paulsen

  • Colo. girl banned from school after shaving head to support cancer-suffering pal allowed back in class - NY Daily News
    http://www.nydailynews.com/news/national/colo-child-kicked-school-shaving-head-sympathy-cancer-pal-article-1.173

    Nine-year-old Kamryn Renfro chose to go bald, with her parents’ approval, to show support for her friend battling cancer and undergoing chemotherapy. Caprock Academy sent her home Monday for violating the dress code, but allowed her back Tuesday after extensive media coverage.

  • Cancer, the Consummate Traveler - Issue 8: Home
    http://nautil.us/issue/8/home/cancer-the-consummate-traveler

    People may call cancer cells all sorts of derogatory names, but homebody isn’t one of them. Born into tumor cells, they relocate to surrounding tissues when their original homes become a toxic mess under the stress of their own overcrowding, the assault of chemotherapy, or when conditions elsewhere seem better. Some oncologists characterize the process of cancer’s spread throughout the body—called metastasis—as a kind of diaspora. And since 90 percent of cancer mortality involves some degree of metastasis, the details of the journey may help researchers strategize against the affliction. “In cancer circles, there’s a kind of dogmatic view: Here’s where cells start and end,” says Bruce Robertson, an ecologist at Bard College in Annandale-on-Hudson, New York. But this perspective ignores many (...)

  • The Rising Costs of Cancer Drugs — New York Magazine
    http://nymag.com/news/features/cancer-drugs-2013-10

    New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars. Prompting some doctors to refuse to use them.

    Avastin, $5,000/month; Zaltrap, $11,000/month; Yervoy, $39,000/month; Provenge, $93,000/course of treatment; Erbitux, $8,400/month; Gleevec, $92,000/year; Tasigna, $115,000/year; Sprycel, $123,000/year.

    #cancer #big_pharma

    In 1965, at the dawn of Medicare, the chemotherapy drug Vinblastine cost $78 a month, according to a widely cited Sloan-Kettering price compendium. In 2011, Bristol-Myers Squibb introduced a new melanoma drug called Yervoy at a cost of about $38,000 a month for a three-month treatment.* Yervoy followed, by about a year, a new prostate-cancer therapy called Provenge that cost $93,000 per course of treatment. Even an ancient chemotherapy like nitrogen mustards, cousins to World War I’s mustard gas and in use since 1949, have gotten caught in the cost updraft; in 2006, a course of treatment experienced a thirteen­fold price increase, from $33 a month to $420 a month.

    (…)

    “What predicts the price of the next cancer drug is the price of the last cancer drug,” says Bach. “The only check on the system is corporate chutzpah.”

    (...)

    Just last week, a New England Journal of Medicine editorial characterized high drug prices as a form of “financial toxicity.”

    (...)

    “Whereas we had hoped that small, incremental gains would be a springboard to something bigger and more productive, I fear those small, incremental gains have become a business model. Right now, it is safer for a pharmaceutical company to strategize for large-scale clinical trials that look for small, incremental gains that will get a drug to market, than to swing for the fences and try for the big advance.”

    It’s not just that the skewed market for cancer drugs rewards mediocre products, he says. “Mediocrity is so well rewarded that it’s a better risk than aiming higher.”

    (...)

    Over the past decade, Kantarjian watched in disbelief as the cost of a successful leukemia drug called #Gleevec rose. “I was shocked that it had tripled since 2001,” he says, “and there was no reason for the increase in price, except that the companies could do it and nobody could do anything about it.” Kantarjian, as established a figure as there is in American oncology, suddenly became #radicalized.

    (...)

    Patients with cancer are 2.5 times as likely to declare bankruptcy as the general population

    (...)

    As a result [of #NICE], a British cancer patient usually pays substantially less than American patients. Gleevec costs about $33,500 a year in England, according to NICE; the U.S. price ranges up to $92,000 (according to the Blood editorial). Tasigna, a newer CML drug, costs about $51,000 in England, while the U.S. price ranges up to $115,000. Sprycel, another new CML drug, costs nearly $49,000 a year in England, while the U.S. price ranges up to $123,000.

    More to the point, NICE has recently said no where Medicare has been forced to say yes. In January 2012, NICE declined to approve Avastin for both colon and breast cancer, and last June, NICE reached the same conclusion about Zaltrap as Sloan-Kettering’s physicians—it declined to cover the use of the drug, considering it too expensive.

  • Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India
    http://www.theatlantic.com/health/archive/2013/04/why-chemotherapy-that-costs-70-000-in-the-us-costs-2-500-in-india/274847

    The international community shows no appetite to agree on new ways to fund pharmaceutical R&D. Talks on alternatives like prize funds and R&D treaties at the World Health Organization have gone nowhere. The United States, Europe, and other developed countries have too much invested in the intellectual property (IP) system.

    #pharma #brevets #santé

    • His manager, Robert Hoy, later issued a statement: "I am very sad to announce that Wilko has recently been diagnosed with terminal cancer of the pancreas. He has chosen not to receive any chemotherapy. He is currently in good spirits, is not yet suffering any physical effects and can expect to enjoy at least another few months of reasonable health and activity. He has just set off on a trip to Japan; on his return we plan to complete a new CD, make a short tour of France, then give a series of farewell gigs in the UK. There is also a live DVD in the pipeline, filmed on the last UK tour.